Cycloastragenol
Based on 10 publication(s) in Google Scholar
Cycloastragenol (Astramembrangenin), the active form of astragaloside IV, has anti-oxidant, anti-inflammatory, anti-aging, anti-apoptotic, and cardiovascular protective effects. Cycloastragenol is a potent telomerase activator and can lengthen telomeres. Cycloastragenol alleviates age-related bone loss and improves bone microstructure and biomechanical properties.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.95%
- No. CAS: 78574-94-4
- Fòrmula: C30H50O5
- Peso molecular:490.72
-
Almacenamiento:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-N0183
FormononetinFGFR2 Inhibitor -
HY-P1149
EpitalonTelomerase Activator -
HY-17353
BIBR 1532Apoptosis Inducer -
HY-N0431
Astragaloside IVMMP Inhibitor -
HY-10219
RapamycinmTOR Inhibitor -
HY-10182
LaduviglusibGSK-3 Inhibitor -
HY-Y0320
Dimethyl sulfoxide, meets analytical specification of Ch.P.Aprotic Solvent -
HY-50856
RuxolitinibJAK1/2 Inhibitor -
HY-N0203
Atractylenolide IIIApoptosis Inducer -
HY-14590
KaempferolEstrogen Receptor α Inhibitor -
HY-16561
ResveratrolPolyphenolic Phytoalexin -
HY-Y0703
Sodium carboxymethyl cellulose (Viscosity:800-1200 mPa.s)Biochemical Assay Reagent
Publications Citing Use of MedChemExpress (MCE) Cycloastragenol
More- Phytother Res. 2026 Apr;40(4):1626-1641. [Abstract]
- Mol Cancer Ther. 2026 Jul 15:10.1158/1535-7163.MCT-26-0182.
- Int J Mol Sci. 2026 Jan 13;27(2):772. [Abstract]
- Int J Mol Sci. 2023 Mar 31;24(7):6554. [Abstract]
- Int J Mol Sci. 2023 Feb 6;24(4):3179. [Abstract]
- J Integr Med. 2024 Jul;22(4):503-514. [Abstract]
- Sci Rep. 2026 Mar 12;16(1):13203. [Abstract]
- J Cell Mol Med. 2026 Apr;30(8):e71128. [Abstract]
- Brain Res Bull. 2026 Jan:234:111689. [Abstract]
- Toxicol Appl Pharmacol. 2023 Sep 15:475:116656. [Abstract]
Customer Validation & Images
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
IF
-
WB
-
IF
Actividad biológica
Descripciòn
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
1.542 μM
Compound: 8
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 28482219] |
| DU-145 | IC50 |
7.258 μM
Compound: 8
|
Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 28482219] |
| HEK293 | IC50 |
127.7 μM
Compound: 8
|
Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 28482219] |
| HeLa | IC50 |
2.198 μM
Compound: 8
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 28482219] |
| MCF7 | IC50 |
1.778 μM
Compound: 8
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 28482219] |
In Vitro
Cycloastragenol (0.03-3 μM; 24-72 hours) promotes viability, osteoblastic differentiation, and mineralization in MC3T3-E1 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 78574-94-4
-
Appearance Solid
-
Peso molecular 490.72
-
Fòrmula C30H50O5
-
Color White to off-white
-
SMILES
CC1(C)[C@@H](O)CC[C@]2(C3)[C@]43CC[C@]5(C)[C@@H]([C@](C)(O6)CC[C@H]6C(C)(O)C)[C@@H](O)C[C@](C)5[C@]4([H])C[C@H](O)[C@@]12[H]
-
Synonyms
Astramembrangenin; Cyclosieversigenin
-
Structure Classification
-
Initial Source
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Phytother Res
Cycloastragenol Alleviates Bone Cancer Pain by Targeting Sirt1 to Inhibit Neuronal Ferroptosis and Promote M2 Microglial Polarization in the Spinal Dorsal Horn of Rats. [Abstract]2026 Apr;40(4):1626-1641. PMID: 41601212
Cycloastragenol purchased from MedChemExpress. Usage Cited in: Phytother Res. 2026 Apr;40(4):1626-1641. [Abstract]
Cycloastragenol (CAG; 20, 100, 500 μg/kg; Intrathecal injection) dose- dependently improved paw withdrawal threshold (PWT) in Bone cancer pain (BCP) rats.
Cycloastragenol purchased from MedChemExpress. Usage Cited in: Phytother Res. 2026 Apr;40(4):1626-1641. [Abstract]
Dose–response relationship of Cycloastragenol (CAG; 125, 250, 375, 500 μg/kg) showed increased antinociceptive effects with higher doses.
Cycloastragenol purchased from MedChemExpress. Usage Cited in: Phytother Res. 2026 Apr;40(4):1626-1641. [Abstract]
Cycloastragenol (CAG; 20, 100, 500 μg/kg; Intrathecal injection) significantly and dose-dependently reduced the Iba-1 expression, with thestrongest inhibition observed at 500 μg/kg in spinal dorsal horn of Bone cancer pain (BCP) rats.
Cycloastragenol purchased from MedChemExpress. Usage Cited in: Phytother Res. 2026 Apr;40(4):1626-1641. [Abstract]
Cycloastragenol (CAG; 20, 100, 500 μg/kg; Intrathecal injection) significantly decreased in Iba-1 protein levels in Bone cancer pain (BCP) rats.
Cycloastragenol purchased from MedChemExpress. Usage Cited in: Phytother Res. 2026 Apr;40(4):1626-1641. [Abstract]
Cycloastragenol (CAG; 20, 100, 500 μg/kg; Intrathecal injection) didnot significantly alter GFAP levels at any dose in spinal dorsal horn of Bone cancer pain (BCP) rats.
-
-
Int J Mol Sci
Cycloastragenol Improves Fatty Acid Metabolism Through NHR-49/FAT-7 Suppression and Potent AAK-2 Activation in Caenorhabditis elegans Obesity Model. [Abstract]2026 Jan 13;27(2):772. PMID: 41596421 -
Int J Mol Sci
Cycloastragenol: A Novel Senolytic Agent That Induces Senescent Cell Apoptosis and Restores Physical Function in TBI-Aged Mice. [Abstract]2023 Mar 31;24(7):6554. PMID: 37047529
Cycloastragenol purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2023 Mar 31;24(7):6554. [Abstract]
Cycloastragenol (CAG; 50,100 μM; 48 h) decreases the expression of PAI-1 and p21 in HELF cells.
-
Int J Mol Sci
2023 Feb 6;24(4):3179. PMID: 36834587 -
J Integr Med
Cycloastragenol induces apoptosis and protective autophagy through AMPK/ULK1/mTOR axis in human non-small cell lung cancer cell lines. [Abstract]2024 Jul;22(4):503-514. PMID: 38849220 -
Sci Rep
Cycloastragenol attenuates osteoarthritis by restoring chondrocyte senescence via the NRF2/NF-κB signaling axis. [Abstract]2026 Mar 12;16(1):13203. PMID: 41813816 -
J Cell Mol Med
Cycloastragenol Inhibits Colorectal Cancer Cell Metastasis via Epithelial-Mesenchymal Transition and the PI3K Signalling Pathway. [Abstract]2026 Apr;30(8):e71128. PMID: 41989454 -
Brain Res Bull
Cycloastragenol protected hippocampal CA1 neurons by regulating redox homeostasis and alleviated cognitive impairment following cerebral ischemia-reperfusion. [Abstract]2026 Jan:234:111689. PMID: 41407128 -
Toxicol Appl Pharmacol
TERT transcription and translocation into mitochondria regulate benzo[a]pyrene/BPDE-induced senescence and mitochondrial damage in mouse spermatocytes. [Abstract]2023 Sep 15:475:116656. PMID: 37579952
Solvente y solubilidad
In Vitro:
DMSO : 66.67 mg/mL (135.86 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.09 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.24 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (280 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Yu Y, et al. Cycloastragenol: An exciting novel candidate for age-associated diseases. Exp Ther Med. 2018;16(3):2175-2182. [Content Brief]
[2]. Li M, et al. Cycloastragenol upregulates SIRT1 expression, attenuates apoptosis and suppresses neuroinflammation after brain ischemia. Acta Pharmacol Sin. 2020;41(8):1025-1032. [Content Brief]
[3]. Yu Y, et al. Cycloastragenol prevents age-related bone loss: Evidence in d-galactose-treated and aged rats. Biomed Pharmacother. 2020;128:110304. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0378 mL | 10.1891 mL | 20.3782 mL | 50.9455 mL |
| 5 mM | 0.4076 mL | 2.0378 mL | 4.0756 mL | 10.1891 mL | |
| 10 mM | 0.2038 mL | 1.0189 mL | 2.0378 mL | 5.0946 mL | |
| 15 mM | 0.1359 mL | 0.6793 mL | 1.3585 mL | 3.3964 mL | |
| 20 mM | 0.1019 mL | 0.5095 mL | 1.0189 mL | 2.5473 mL | |
| 25 mM | 0.0815 mL | 0.4076 mL | 0.8151 mL | 2.0378 mL | |
| 30 mM | 0.0679 mL | 0.3396 mL | 0.6793 mL | 1.6982 mL | |
| 40 mM | 0.0509 mL | 0.2547 mL | 0.5095 mL | 1.2736 mL | |
| 50 mM | 0.0408 mL | 0.2038 mL | 0.4076 mL | 1.0189 mL | |
| 60 mM | 0.0340 mL | 0.1698 mL | 0.3396 mL | 0.8491 mL | |
| 80 mM | 0.0255 mL | 0.1274 mL | 0.2547 mL | 0.6368 mL | |
| 100 mM | 0.0204 mL | 0.1019 mL | 0.2038 mL | 0.5095 mL |
Cycloastragenol Related Classifications
HY-N1485 Related Classifications
Powered by Bioz